Jim is Managing Director of Retrogenix, having co-founded the company in 2008. This followed 10+ years in management within the biotechnology (Oxford BioMedica) and pharmaceutical industry (AstraZeneca). He is a biologist by training, and obtained his PhD at Manchester University, UK, in 1997.
WIC 2017 Day 1, Tuesday 31st October 2017 @ 11:35
Plenary roundtable session9 senior level tables hosted by thought leaders on key challenges and opportunities in antibody drug development. Participants are invited to join the group discussions on a topic of importance to them.
TABLE 3 Assessing target specificity of biotherapeutics
back to speakers